



oxiconazole (Oxistat 1%)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

oxiconazole (Oxistat 1%)	1
Summary	2
Definitions	2
Clinical Indications	3
Medical Necessity Criteria for Clinical Review	3
General Medical Necessity Criteria	3
Fungal Infections	3
Experimental / Investigational, or unproven	3
References	3
Clinical Guideline Revision / History Information	4

Summary

Dermatophyte (tinea) infections are often superficial fungal infections, typically caused by *Trichophyton*, *Epidermophyton* or *Microsporum*. Symptoms of skin fungal infection are dependent upon the type of infection (i.e., Tinea Pedis, tinea corporis, tinea cruris, or tinea pityriasis), but can include itching, skin flaking, redness, and soreness. Management typically includes topical antifungal therapies (e.g. clotrimazole, econazole, efinaconazole, ketoconazole, miconazole, oxiconazole, naftifine, terbinafine, butenafine, ciclopirox, tavaborole, or tolnaftate) and rarely require oral therapy except in the cases of severe, refractory or extensive infections.

Oxiconazole (Oxistat 1%) is a topical antifungal agent approved by the FDA for managing superficial fungal infections of the skin caused by a variety of dermatophytes and yeast. This drug can be administered to both pediatrics and adults and is available in two commercial formulations: cream and lotion. The most frequently observed side effects include itching and irritation at the site of application, which may manifest as pain, burning, or stinging.

Definitions

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Tinea" refers to a group of contagious fungal infections caused by dermatophytes, a type of fungus. These infections can manifest on various body parts and are usually named for the body area affected.

"Tinea corporis" describes a fungal infection on body surfaces not including the feet, groin, face, scalp hair, or beard hair. It's commonly known as "ringworm" due to its characteristic ring-shaped rash.

"Tinea cruris" refers to a fungal infection in the groin region, proximal inner thighs, or buttocks. It's often referred to as "jock itch."

"Tinea pedis" pertains to a fungal infection of the feet, commonly known as "athlete's foot."

"Tinea versicolor" is a non-contagious skin condition caused by an overgrowth of certain types of yeast present on skin. This results in discoloration, with patches of skin appearing lighter or darker than the surrounding skin. These patches are most common on the trunk and shoulders.

"[s]" indicates state mandates may apply.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

Fungal Infections

The Plan considers oxiconazole (Oxistat 1%) medically necessary when BOTH of the following criteria are met:

1. The member has ONE (1) of the following as a documented diagnosis:
 - a. Tinea corporis (ringworm); *or*
 - b. Tinea cruris (jock itch); *or*
 - c. Tinea pedis (athlete's foot); *or*
 - d. Tinea (pityriasis) versicolor; *AND*
2. The member is unable to use, or has tried and failed TWO (2) of the following^[s]:
 - a. butenafine cream over-the-counter (OTC); *and/or*
 - b. ciclopirox cream, gel, or suspension; *and/or*
 - c. clotrimazole cream or solution OTC; *and/or*
 - d. econazole cream; *and/or*
 - e. ketoconazole cream or shampoo; *and/or*
 - f. luliconazole cream; *and/or*
 - g. miconazole cream OTC; *and/or*
 - h. naftifine cream; *and/or*
 - i. selenium sulfide; *and/or*
 - j. terbinafine cream OTC; *and/or*
 - k. tolnaftate cream OTC; *AND*
3. Oxiconazole (Oxistat 1%) is being prescribed at a dose and frequency that is within FDA approved labeling *OR* is supported by compendia or evidence-based published dosing guidelines for the requested indication.

If the above prior authorization criteria are met, the requested product will be approved for up to 6 months.^[s]

Experimental / Investigational, or unproven^[s]

Oxiconazole (Oxistat 1%) for any other use is considered experimental, investigational, or unproven.

References

1. Burke D and Chi E. Tinea Versicolor. Available at: <https://www.healthline.com/health/tinea-versicolor>. Last Updated March 2019. Accessed Sept 2021.
2. Caplan AS, Gold JAW, Smith DJ, Ely JW. Diagnosis and Management of Tinea Infections. Am Fam Physician. 2025 Oct;112(4):382-392. PMID: 41118183.

3. Dermatological Therapies: American Academy of Dermatology. Available at: www.aad.org. Accessed Sept 2021.
4. Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. *Cutis*. 1996 Oct;58(4):305-7. PMID: 8894432.
5. Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. *Am Fam Physician*. 2014 Nov 15;90(10):702-10.
6. Genuino RNF, Dofitas BL, Batac MCFR, Pascual MBTG, Abrilla AA. Systematic Review and Meta-analysis on Synthetic Antifungal versus Keratolytic Agents for Topical Treatment of Pityriasis Versicolor. *Acta Med Philipp*. 2024 Jan 26;58(1):64-78. doi: 10.47895/amp.vi0.5605.
7. Goldstein, AO and Goldstein BG. Dermatophyte (tinea) infections - UpToDate. Available at: <https://www.uptodate.com/contents/dermatophyte-tinea-infections>. Last Updated May 2021. Accessed Sept 2021.
8. Hoopes RR, Travers JB. Exaggerated Immune Reaction to Trichophyton Fungus Results in an Inflammatory Tinea Pedis. *Arch Intern Med Res*. 2020;3(3):183-185. doi:10.26502/aimr.0040
9. Jartarkar SR, Patil A, Goldust Y, et al. Pathogenesis, Immunology and Management of Dermatophytosis. *J Fungi (Basel)*. 2021;8(1):39. Published 2021 Dec 31. doi:10.3390/jof8010039
10. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea versicolor: an updated review. *Drugs Context*. 2022 Nov 14;11:2022-9-2. doi: 10.7573/dic.2022-9-2.
11. Leung AK, Lam JM, Leong KF, Hon KL. Tinea corporis: an updated review. *Drugs Context*. 2020;9:2020-5-6. Published 2020 Jul 20. doi:10.7573/dic.2020-5-6
12. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, CO. Available at: <http://www.micromedexsolutions.com/>. Accessed Sept 2021.
13. Oxistat (oxiconazole nitrate) lotion [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; May 2022.
14. Oxistat (oxiconazole nitrate) cream [prescribing information]. Melville, NY: PharmaDerm; January 2012.
15. Oxistat [package insert]. Melville, NY: E. Fougera & CO; February 2019.
16. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. *Indian Dermatol Online J*. 2016 Mar-Apr;7(2):77-86. doi: 10.4103/2229-5178.178099.
17. van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. *Br J Dermatol*. 2015 Mar;172(3):616-41. doi: 10.1111/bjd.13441. Epub 2015 Feb 9. PMID: 25294700.

Clinical Guideline Revision / History Information

Original Date: 10/14/2021

Reviewed/Revised: 12/01/2021, 06/23/2022, 06/29/2023, 12/19/2024, 10/01/2025, 12/01/2026